<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982487</url>
  </required_header>
  <id_info>
    <org_study_id>I 243013</org_study_id>
    <secondary_id>NCI-2013-02080</secondary_id>
    <secondary_id>080913</secondary_id>
    <secondary_id>SRC1 082013</secondary_id>
    <secondary_id>IRB 100313</secondary_id>
    <secondary_id>SRC2 082713</secondary_id>
    <secondary_id>I 243013</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT01982487</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission</brief_title>
  <official_title>A Phase I/IIb Study of Recombinant ALVAC(2)-NY-ESO-1 (M)/TRICOM in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase I/IIb trial studies the side effects vaccine therapy and&#xD;
      indoleamine 2,3-dioxygenase (IDO1) inhibitor 4-amino-1,2,5-oxadizaole-3-carboximidamide&#xD;
      (INCB024360) and to see how well they work in treating patients with epithelial ovarian,&#xD;
      fallopian tube, or primary peritoneal cancer who are in remission. Vaccines made from&#xD;
      gene-modified virus may help the body build an effective immune response to kill tumor cells.&#xD;
      IDO1 inhibitor INCB024360 may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving vaccine therapy with IDO1 inhibitor INCB024360 may be an&#xD;
      effective treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety of fixed doses of the modified canarypox vector&#xD;
      (ALVAC[2])-cancer/testis antigen 1B (NY-ESO-1) (M)/triad of costimulatory molecules (TRICOM)&#xD;
      vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To evaluate&#xD;
      toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria for&#xD;
      Adverse Events (CTCAE) version 4.0. (Phase I) III. To determine the progression free survival&#xD;
      (PFS) using standard imaging response (Response Evaluation Criteria in Solid Tumors [RECIST]&#xD;
      1.1) criteria. (Phase IIb)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing&#xD;
      NY-ESO-1 specific cellular and humoral immunity in peripheral blood NY-ESO-1 specific CD8+&#xD;
      and CD4+ T cells.&#xD;
&#xD;
      II. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing&#xD;
      NY-ESO-1 specific cellular and humoral immunity in peripheral blood NY-ESO-1 specific&#xD;
      antibodies.&#xD;
&#xD;
      III. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing&#xD;
      NY-ESO-1 specific cellular and humoral immunity in peripheral blood frequency of&#xD;
      CD4+CD25+FOXP3+ regulatory T cells.&#xD;
&#xD;
      IV. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing&#xD;
      NY-ESO-1 specific cellular and humoral immunity in pharmacokinetics (PK) of IDO in relation&#xD;
      to T cell frequency and function in correlation with PFS.&#xD;
&#xD;
      OUTLINE: This is a Phase I study followed by a randomized Phase IIb study.&#xD;
&#xD;
      PHASE I: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine subcutaneously (SC) on day 1&#xD;
      and IDO1 inhibitor INCB024360 orally (PO) twice daily (BID) on days 1-28. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      PHASE IIb: Patients are randomized to 1 of 4 arms.&#xD;
&#xD;
      ARM A: Patients receive no treatment.&#xD;
&#xD;
      ARM B: Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.&#xD;
&#xD;
      ARM C: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor&#xD;
      INCB024360 PO BID on days 1-28.&#xD;
&#xD;
      ARM D: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.&#xD;
&#xD;
      In all arms, treatment repeats every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6 weeks; at 3, 6, and 12&#xD;
      months; and then annually for up to 15 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of IDO1 inhibitor INCB024360, determined by incidence of dose limiting toxicities graded according to the NCI CTCAE version 4.0 (Phase I)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS (Phase IIb)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The primary analysis will be carried forth using a Cox proportional hazards model with factors corresponding to treatment combination, IDO1 inhibitor INCB024360 (yes/no) and ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine (yes/no), a continuous covariate adjustment for the length of the treatment free interval and a blocking factor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Immunological parameters (antibody titres, NY-ESO-1 specific CD8+ and CD4+ frequency and function, frequency of memory T cell populations, TCR avidity, secondary recall response) will be analyzed in a straightforward analysis-of-covariance (ANCOVA) fashion modeling post-treatment levels as a function of pre-treatment levels with factors corresponding to IDO1 inhibitor INCB024360 (yes/no) and ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rate, graded according to NCI CTCAE version 4.0</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The toxicity rate will be estimated using a one-sided, 95%, exact binomial confidence interval (Clopper-Pearson). The lower one sided limit will be used.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Recurrent Fallopian Tube Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IA Fallopian Tube Cancer</condition>
  <condition>Stage IA Ovarian Epithelial Cancer</condition>
  <condition>Stage IA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IB Fallopian Tube Cancer</condition>
  <condition>Stage IB Ovarian Epithelial Cancer</condition>
  <condition>Stage IB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IC Fallopian Tube Cancer</condition>
  <condition>Stage IC Ovarian Epithelial Cancer</condition>
  <condition>Stage IC Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIA Fallopian Tube Cancer</condition>
  <condition>Stage IIA Ovarian Epithelial Cancer</condition>
  <condition>Stage IIA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIB Fallopian Tube Cancer</condition>
  <condition>Stage IIB Ovarian Epithelial Cancer</condition>
  <condition>Stage IIB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIC Fallopian Tube Cancer</condition>
  <condition>Stage IIC Ovarian Epithelial Cancer</condition>
  <condition>Stage IIC Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIIA Fallopian Tube Cancer</condition>
  <condition>Stage IIIA Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIIB Fallopian Tube Cancer</condition>
  <condition>Stage IIIB Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIIC Fallopian Tube Cancer</condition>
  <condition>Stage IIIC Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIC Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IV Fallopian Tube Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (no treatment)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive no treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (vaccine, IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm C (vaccine, IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm D (vaccine)</arm_group_label>
    <other_name>vCP2292</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDO1 inhibitor INCB024360</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm C (vaccine, IDO1 inhibitor INCB024360)</arm_group_label>
    <other_name>INCB024360</other_name>
    <other_name>indoleamine-2,3-dioxygenase inhibitor INCB024360</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm B (IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm C (vaccine, IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm D (vaccine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm B (IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm C (vaccine, IDO1 inhibitor INCB024360)</arm_group_label>
    <arm_group_label>Arm D (vaccine)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and no&#xD;
             evidence of disease or no measurable disease after 1st or 2nd line therapy; these&#xD;
             patients would normally enter a period of observation after standard management&#xD;
&#xD;
          -  Any human leukocyte antigen (HLA) type; historic HLA typing is permitted&#xD;
&#xD;
          -  Tumor expression of NY-ESO-1 or cancer/testis antigen 2 (LAGE-1) by&#xD;
             immunohistochemistry (IHC) and/or reverse transcription-polymerase chain reaction&#xD;
             (RTPCR)&#xD;
&#xD;
          -  No allergy to eggs&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Hematology and biochemistry laboratory results within the limits normally expected for&#xD;
             the patient population, without evidence of major organ failure&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/uL&#xD;
&#xD;
          -  Platelet count (PLT) &gt;= 75,000/uL&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 8g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum aspartate aminotransferase (serum glutamic oxalacetic transaminase&#xD;
             [SGOT]/aspartate aminotransferase [AST]) or serum alanine aminotransferase (serum&#xD;
             glutamate pyruvate transaminase [SGPT]/alanine aminotransferase [ALT]) =&lt; 3 x ULN&#xD;
&#xD;
          -  Serum creatinine =&lt; 2 x ULN&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) =&lt; 1.5&#xD;
&#xD;
          -  Have been informed of other treatment options&#xD;
&#xD;
          -  Patient or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2&#xD;
&#xD;
          -  The ability to swallow and retain oral medication&#xD;
&#xD;
          -  Patients of child-bearing potential must agree to use acceptable contraceptive methods&#xD;
             (e.g., double barrier) during treatment&#xD;
&#xD;
          -  Patients may have received previous NY-ESO-1 vaccine therapy; patients who received&#xD;
             maintenance paclitaxel or bevacizumab are eligible for enrollment provided they have&#xD;
             discontinued therapy (at least 4 weeks for prior taxane) prior to randomization and&#xD;
             recovered from toxicities to less than grade 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease to the central nervous system for which other therapeutic options,&#xD;
             including radiotherapy, may be available&#xD;
&#xD;
          -  Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding&#xD;
             disorders)&#xD;
&#xD;
          -  History of autoimmune disease (e.g. thyroiditis, lupus) except vitiligo&#xD;
&#xD;
          -  Concomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal&#xD;
             anti-inflammatory drugs, and other platelet inhibitory agents&#xD;
&#xD;
          -  Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing&#xD;
             of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast&#xD;
             cancers are allowed&#xD;
&#xD;
          -  Clinically significant heart disease (New York Heart Association [NYHA] class III or&#xD;
             class IV) within 6 months&#xD;
&#xD;
          -  Participation in any other clinical trial involving another investigational agent&#xD;
             within 4 weeks prior to first dosing of study drug&#xD;
&#xD;
          -  Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Mental impairment that may compromise the ability to give informed consent and comply&#xD;
             with the requirements of the study&#xD;
&#xD;
          -  Lack of availability of a patient for immunological and clinical follow-up assessment&#xD;
&#xD;
          -  Evidence of current drug or alcohol abuse or psychiatric impairment, which in the&#xD;
             investigator's opinion will prevent completion of the protocol therapy or follow-up&#xD;
&#xD;
          -  Pregnant or nursing female patients&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the patient an unsuitable&#xD;
             candidate to receive study drug (i.e., any significant medical illness or abnormal&#xD;
             laboratory finding that would, in the investigator's judgement, increase the patient's&#xD;
             risk by participating in this study)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunle Odunsi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

